5 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
Follow Recurrent Kaposi Sarcoma: new trials by email Literature Review of Recurrent Kaposi Sarcoma trials Research Report on Recurrent Kaposi Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Biospecimen Collection - Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm | Recruiting | AIDS Malignancy Consortium | 200 | 2023-05-10 | 2026-06-01 | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Laboratory Biomarker Analysis, Nelfinavir Mesylate - Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma | Phase 2 | Completed | AIDS Malignancy Consortium | 36 | 2017-03-13 | 2025-12-17 |
| Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma gamma secretase inhibitor PF-03084014, pharmacological study, laboratory biomarker analysis - AIDS-related Kaposi Sarcoma, HIV Infection | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2015-07-01 | 2015-07-23 | |
| Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Lenalidomide - AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 38 | 2010-08-27 | 2022-02-08 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration - AIDS-Related Kaposi Sarcoma, HIV Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2010-01-22 | 2018-02-20 |
| Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma halofuginone hydrobromide, placebo, laboratory biomarker analysis - AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2003-05-01 | 2013-06-05 |
Sarcoma, Kaposi (8) · HIV Infections (5) · AIDS-related Kaposi sarcoma (4) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Chondrosarcoma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1) · Desmoplastic Small Round Cell Tumor (1) · Fibrosarcoma (1) · Gastrointestinal Stromal Tumors (1)
DNA Virus Infections (8) · Herpesviridae Infections (8) · Infections (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms, Vascular Tissue (8) · Virus Diseases (8) · Sarcoma (7) · Blood-Borne Infections (5) · Communicable Diseases (5) · Genital Diseases (5) · Immune System Diseases (5) · Immunologic Deficiency Syndromes (5) · Lentivirus Infections (5)
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bortezomib (1) · HhAntag691 (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · Nelfinavir (1) · Nivolumab (1) · Specimen Handling (1) · cabozantinib (1) · halofuginone (1) · nirogacestat (1)
National Cancer Institute (NCI) (5) · AIDS Malignancy Consortium (3)
United States (7) · South Africa (1) · Uganda (1)
Erin Reid (1) · Haiying Cheng (1) · Jeff Bethony (1) · Kelly Shimabukuro (1) · Lee Ratner (1) · Mrinal Gounder (1) · Soren Gantt (1) · Susan Krown (1)
PMID 27002157, PMID 35247913, PMID 42847673
U01CA121947 (3), UM1CA121947 (2), 2UM1CA121947 (1), N01CM62206 (1), P30CA008748 (1), U01CA069856 (1), U01CA070019 (1)